After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will ...

Despite the availability of long-term prophylaxis (LTP), a substantial proportion of patients with hereditary angioedema (HAE) in Sweden continue to require repeated on-demand or short-term treatments ...

Ionis IONS and its Japanese partner, Otsuka Pharmaceutical, announced that the European Commission has approved Dawnzera (donidalorsen) for the prevention of recurrent attacks of hereditary angioedema ...

Takhzyro (lanadelumab-flyo) is a biologic medicine used to prevent hereditary angioedema (HAE) attacks in people who are 2 years or older. During an HAE attack, swelling under the skin happens in ...

Even if you’re doing everything you can to avoid an episode of hereditary angioedema (HAE) — dodging injuries, preventing respiratory illnesses, taking medication — it’s not always possible to ward ...

The European Commission has approved Otsuka's Dawnzera for the prevention of recurrent attacks in rare disease hereditary angioedema (HAE), a drug that can be self-administered by patients with weeks ...

ATTR program on hold amid safety risks; HAE therapy faces tough rivals and small market. Read more analysis here.

Deucrictibant significantly improved the time to onset of symptom relief, defined as PGI-C of at least “a little better”, compared with placebo (1.28 vs >12 hours). Topline data were announced from a ...

The goal of acute treatment of an hereditary angioedema (HAE) attack is to reduce its duration and severity and thus limit its impact on the patient’s functional ability and prevent a potentially ...

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted ...